Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac
function and reduces scar. These effects occur via stimulation of endogenous repair …

The vascular endothelial growth factor (VEGF), a homodimeric vasoactive glycoprotein, is
the key mediator of angiogenesis. Angiogenesis, the formation of new blood vessels, is …

Importance Stem cell therapy is a promising treatment strategy for patients with heart failure,
which accounts for more than 10% of deaths in the United States annually. Despite more …

Poor functional survival of the engrafted stem cells limits the therapeutic efficacy of stem-cell-
based therapy for myocardial infarction (MI). Cardiac patch-based system for cardiac repair …

Aims Recent evidence suggests that cardiac progenitor cells (CPCs) may improve cardiac
function after injury. The underlying mechanisms are indirect, but their mediators remain …

Extracellular vesicles (EVs) derived from various stem cell sources induce cardioprotective
effects during ischemia-reperfusion injury (IRI). These have been attributed mainly to the …

Cell therapy continues to attract growing interest as a promising approach to treat a variety
of diseases. Mesenchymal stem cells (MSCs) have been one of the most intensely studied …

Hematopoietic stem cells (HSCs) are regarded as one of essential cell sources for treating
regenerative diseases. Among many stem cells, the feasibility of using adult-derived …

Perhaps the most important advance in the field of cell therapy for heart disease has been
the recognition that all stem/progenitor cells (both adult and embryonic) fail to engraft in the …

Rationale: Cardiac progenitor cells (CPCs) improve left ventricular remodeling and function
after acute or chronic myocardial infarction. However, the long-term (> 5 weeks) effects …